article
Exploring the need for mutation-specific treatments in cystic fibrosis
Despite that over 1,900 mutations of the cystic fibrosis transmembrane conductance regulator cause cystic fibrosis, only two treatment options exist.
List view / Grid view
Caroline Richards (Drug Target Review)
article
Personalised Medicines In-Depth Focus 2016
In this Personalised Medicines In-Depth Focus, Dr Adrian Harel talks about the importance of developing a diagnostic test and better treatments for traumatic brain injury. Plus, Caroline Richards, Editor of Drug Target Review explores the need for mutation specific treatments in cystic fibrosis...
article
Rare Diseases Q&A
Releasing colourful balloons into the air to symbolise people who are affected by rare diseases was one of the many ways in which this year’s Rare Disease Day was marked in February. The once-yearly, global campaign aims to raise awareness among the general public and decision-makers about these illnesses and…
article
Interview with Amrik Basran, Chief Scientific Officer at Avacta Life Sciences
Caroline Richards, Editor of Drug Target Review, asks Amrik Basran, Chief Scientific Officer at Avacta Life Sciences, to provide his views on Affimer® technology...
article
Meet the editorial board members who influenced the Spring 2015 issue
Editor Caroline Richards talks about the editorial board members who have influenced the content coming up in the latest issue of Drug Target Review, available in April 2015...
article
How next-generation sequencing came to be: a brief history
DNA sequencing technologies have come on leaps and bounds since the double-helical structure of DNA was first discovered in 1953 by genetics pioneers James Watson and Francis Crick. This discovery paved the way to the development, years later, of next generation sequencing (NGS), a high-throughput technology that enables scientists to…